World's Best Scientists 2026 revealed!
Gert J. Ossenkoppele

Gert J. Ossenkoppele

D-Index & Metrics

Medicine

D-Index
99
Citations
45764
World Ranking
8470
National Ranking
331

Gert J. Ossenkoppele publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gert J. Ossenkoppele sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 679 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gert J. Ossenkoppele D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gert J. Ossenkoppele sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gert J. Ossenkoppele is affiliated with the University of Amsterdam in the Netherlands. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a notable focus on Hematology, Molecular Biology, Genetics, Public Health, Environmental and Occupational Health, and Cancer Research. This interdisciplinary approach underscores their integration of clinical and molecular perspectives in medical science.

The scientist has extensively contributed to the study of hematologic malignancies, particularly on Acute Myeloid Leukemia (AML). Their work encompasses topics such as Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia research, Chronic Myeloid Leukemia Treatments, Myeloproliferative Neoplasms: Diagnosis and Treatment, Cancer Genomics and Diagnostics, and Histone Deacetylase Inhibitors Research.

Key recent publications include:

  • "Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN" (2022, Blood)
  • "2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party" (2021, Blood)
  • "Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission" (2020, New England Journal of Medicine)
  • "Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome" (2022, Blood)
  • "Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study" (2020, Blood)

Ossenkoppele's frequent co-authors illustrate a close collaboration network and include Jacqueline Cloos, Bob Löwenberg, Peter J.M. Valk, Jeroen J. W. M. Janssen, and Lok Lam Ngai. These collaborations likely support multidisciplinary approaches and extensive clinical research efforts.

The scientist has published predominantly in the following venues:

  • Blood
  • Leukemia
  • HemaSphere
  • Journal of Clinical Oncology
  • Blood Advances

In addition to journal articles, Ossenkoppele has contributed to academic literature through book publication. One known title is Acute Myeloid Leukemia, published in 2021 by Springer International Publishing.

Best Publications

  • Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

    Hartmut Döhner;Elihu Estey;David Grimwade;Sergio Amadori

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

    Hagop M. Kantarjian;Francis Giles;Norbert Gattermann;Kapil Bhalla

  • Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

    Gerrit J. Schuurhuis;Michael Heuser;Sylvie Freeman;Marie Christine Béne

  • High-dose daunorubicin in older patients with acute myeloid leukemia.

    Bob Löwenberg;Gert J. Ossenkoppele;Wim van Putten;Harry C. Schouten

  • A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia

    A.A. van de Loosdrecht;R.H.J. Beelen;G.J. Ossenkoppele;M.G. Broekhoven

  • Molecular Minimal Residual Disease in Acute Myeloid Leukemia

    Mojca Jongen-Lavrencic;Tim Grob;Diana Hanekamp;François G Kavelaars

  • Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study

    Martin Klein;JJ Heimans;NK Aaronson;HM van der Ploeg

  • Prognostic Index for Adult Patients With Acute Myeloid Leukemia in First Relapse

    Dimitri A. Breems;Wim L.J. Van Putten;Peter C. Huijgens;Gert J. Ossenkoppele

  • Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

    Joerg Hasford;Michele Baccarani;Verena Hoffmann;Joelle Guilhot

  • The novel AML stem cell–associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells

    Anna Van Rhenen;Guus A.M.S. Van Dongen;Angè Le Kelder;Elwin J. Rombouts

  • Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

    Susanne Saussele;Johan Richter;Joelle Guilhot;Franz X Gruber

  • High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

    Monique Terwijn;Wim L J van Putten;Angèle Kelder;Vincent H J van der Velden

  • High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival.

    Anna van Rhenen;Nicole Feller;Angèle Kelder;August H. Westra

  • Cytarabine dose for acute myeloid leukemia.

    Bob Lowenberg;Thomas Pabst;Edo Vellenga;Wim van Putten

  • 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.

    Michael Heuser;Sylvie D Freeman;Gert J Ossenkoppele;Francesco Buccisano

  • The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

    Jan J. Cornelissen;Alois Gratwohl;Richard F. Schlenk;Jorge Sierra

  • Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

    Miguel A. Sanz;Pau Montesinos;Chelo Rayón;Alexandra Holowiecka

  • High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani;Claudia Erpelinck;Wim L. J. van Putten;Peter J. M. Valk

  • BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

    Matthew S. Zabriskie;Christopher A. Eide;Christopher A. Eide;Srinivas K. Tantravahi;Nadeem A. Vellore

  • High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities

    Stefan Gröschel;Sanne Lugthart;Richard F. Schlenk;Peter J.M. Valk

Frequent Co-Authors

Bob Löwenberg
Bob Löwenberg Erasmus MC
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Sonja Zweegman
Sonja Zweegman Amsterdam UMC
Edo Vellenga
Edo Vellenga University Medical Center Groningen
Peter J. M. Valk
Peter J. M. Valk Erasmus University Rotterdam
Jan J. Cornelissen
Jan J. Cornelissen Erasmus University Rotterdam
Michele Baccarani
Michele Baccarani University of Bologna
Jeroen J. L. M. Cornelissen
Jeroen J. L. M. Cornelissen University of Twente

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens doors to a range of allied health careers and educational options, many of which can be pursued online for greater flexibility and affordability. For those interested in pharmacy, finding the best online pharmacy school can help you start or advance your career without interrupting your current commitments.

Another growing field is Health Information Management, where rhia certification programs online allow you to gain recognized credentials to manage medical data and records.

If you’re more interested in the administrative side, you may be wondering how much is medical billing and coding school. Online programs in this area are typically short-term and highly affordable.

Finally, nursing remains a popular pathway, and aspiring nurse practitioners are often looking for cheap online fnp programs (family nurse practitioner programs) to advance their careers efficiently and cost-effectively.

Best Scientists Citing Gert J. Ossenkoppele

Trending Scientists

Recently Published Articles